Compare Abbott Laboratories (ABT) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Xpeng Inc - ADR — how do they compare? Abbott Laboratories trades at $95.55 (market cap $166.94B), while Xpeng Inc - ADR trades at $13.18 (market cap $12.75B). The key difference: Abbott Laboratories is far larger — about 13.1× Xpeng Inc - ADR's market cap, and Abbott Laboratories pays a 2.63% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| ABT | XPEV | |
|---|---|---|
Market Cap | $166.94B | $12.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $28.07 |
52-Week Low | $82.57 | $12.09 |
Enterprise Value | $193.69B | $14.86B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
XPeng (XPEV) trades at $13.17, up 0.69% today, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with negative profitability ratios. Recent news highlights vehicle delivery growth and advancements in autonomous driving technology, but the stock faces headwinds from broader EV sector challenges.
The outlook remains cautious due to persistent losses and competitive pressures, though analyst consensus is bullish with 64.7% buy ratings. Key risks include execution on profitability, intense EV competition, and regulatory uncertainties. Revenue expansion and technology innovation present opportunities if the company can achieve sustained margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
